Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859377 | 1.00 | LSS (0.39) | LSSTRPV1TSHRHTTFAAH | |
| SCHEMBL11293116 | 0.81 | NDUFS8 (0.45) | LSSTRPV1TSHRHTTCA1 | |
| SCHEMBL11293118 | 0.81 | NDUFS8 (0.45) | LSSTRPV1TSHRHTTCA1 | |
| SCHEMBL2863861 | 0.81 | NDUFS8 (0.39) | TRPV1ALDH1A1KMT2A | |
| SCHEMBL2867599 | 0.78 | FAAH (0.40) | TSHRHTTFAAHALDH1A1CA1 | |
| SCHEMBL2867602 | 0.78 | FAAH (0.40) | TSHRHTTFAAHALDH1A1CA1 | |
| SCHEMBL9508252 | 0.76 | TSHR (0.47) | LSSTRPV1TSHRHTTALOX5 | |
| SCHEMBL9508258 | 0.76 | TSHR (0.47) | LSSTRPV1TSHRHTTALOX5 | |
| SCHEMBL2866740 | 0.76 | PTPN1 (0.33) | LSS | |
| SCHEMBL2866741 | 0.76 | PTPN1 (0.33) | LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728180-B2 | Method for producing ethers | KURARAY CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080262272-A1 | Method For Producing Ethers | KURARAY CO., LTD. (JP) | 2008-10-23 | — | — | US | disclosed |
| CN-1972888-A | Method for producing ethers | KURARAY CO (JP) | 2007-05-30 | — | — | CN | disclosed |
| EP-1760061-A1 | METHOD FOR PRODUCING ETHERS | KURARAY CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262272-A1 | Method For Producing Ethers | TELO2, PDS5A, TERT | LSS 1302/4885TRPV1 4274/4885TSHR 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.